AstraZeneca Revises US Clinical Results... Lowers Prevention Effectiveness by 3%P

[Image source=Reuters Yonhap News]

[Asia Economy Reporter Cho Hyun-ui] AstraZeneca lowered the preventive efficacy of its COVID-19 vaccine by 3 percentage points from the previous 79% in clinical trial results conducted in the United States on the 25th (local time). This came after U.S. health authorities raised suspicions that the additional clinical trial results conducted in the U.S. might have included outdated information.

According to major foreign media, AstraZeneca revised the efficacy of its vaccine to 76% based on clinical trials involving about 30,000 people in the U.S. on the same day. This is lower than the 79% announced on the 21st.

The U.S. National Institute of Allergy and Infectious Diseases (NIAID) announced on the 23rd that it had been informed by the Data and Safety Monitoring Board (DSMB) that the large-scale clinical trial results conducted by AstraZeneca in the U.S. might have included outdated information. The DSMB expressed concerns that "if outdated information is included, the vaccine efficacy data cannot be fully assessed."

In response, AstraZeneca stated, "We will immediately cooperate with the DSMB to share an initial analysis based on the latest efficacy data and announce the results within 48 hours," and then released the revised preventive efficacy on the same day.

Based on the additional clinical results conducted in the U.S., AstraZeneca plans to apply for emergency use authorization from the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) in early to mid-next month.

This content was produced with the assistance of AI translation services.